
A late-stage study found the drug combination lowered the risk of death and extended median survival for patients with extensive-stage disease.
Adding Amgen’s Imdelltra to AstraZeneca’s Imfinzi lowered the risk of death by 58% in a late-stage trial of patients with extensive-stage small cell lung cancer. Median overall survival was 21.1 months with the combination, compared with 12.7 months with Imfinzi alone.
The trial tested the combination as maintenance therapy for patients whose cancer had not progressed after initial treatment with Imfinzi and chemotherapy. Amgen said nearly 80% of patients who began both drugs were alive at one year, compared with 53% of those taking Imfinzi alone.
Lead investigator Dr. Jacob Sands said benefits were seen across patient subgroups, including people whose cancer had spread to the brain or liver. He said longer follow-up could change the median survival result.
Imdelltra is currently approved for patients whose small cell lung cancer progresses during or after platinum-based chemotherapy. The study did not compare the combination with other first-line treatment approaches.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.